Literature DB >> 33414394

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.

Francesca Palandri1, Giuseppe Alberto Palumbo2, Elena Maria Elli3, Nicola Polverelli4, Giulia Benevolo5, Bruno Martino6, Elisabetta Abruzzese7, Mario Tiribelli8, Alessia Tieghi9, Roberto Latagliata10, Francesco Cavazzini11, Micaela Bergamaschi12, Gianni Binotto13, Monica Crugnola14, Alessandro Isidori15, Giovanni Caocci16, Florian Heidel17, Novella Pugliese18, Costanza Bosi19, Daniela Bartoletti20, Giuseppe Auteri20, Daniele Cattaneo21, Luigi Scaffidi22, Malgorzata Monica Trawinska7, Rossella Stella8, Fiorella Ciantia23, Fabrizio Pane18, Antonio Cuneo11, Mauro Krampera22, Gianpietro Semenzato13, Roberto Massimo Lemoli12, Alessandra Iurlo21, Nicola Vianelli20, Michele Cavo20, Massimo Breccia10, Massimiliano Bonifacio22.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33414394      PMCID: PMC7791065          DOI: 10.1038/s41408-020-00392-1

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  13 in total

1.  Ruxolitinib withdrawal syndrome leading to tumor lysis.

Authors:  Tong Dai; Ellen W Friedman; Stefan K Barta
Journal:  J Clin Oncol       Date:  2013-06-10       Impact factor: 44.544

2.  A life-threatening ruxolitinib discontinuation syndrome.

Authors:  Giacomo Coltro; Francesco Mannelli; Paola Guglielmelli; Annalisa Pacilli; Alberto Bosi; Alessandro Maria Vannucchi
Journal:  Am J Hematol       Date:  2017-06-01       Impact factor: 10.047

3.  Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Authors:  Francesca Palandri; Giuseppe A Palumbo; Massimiliano Bonifacio; Massimo Breccia; Roberto Latagliata; Bruno Martino; Nicola Polverelli; Elisabetta Abruzzese; Mario Tiribelli; Maura Nicolosi; Micaela Bergamaschi; Alessia Tieghi; Alessandra Iurlo; Nicola Sgherza; Francesco Cavazzini; Alessandro Isidori; Gianni Binotto; Adalberto Ibatici; Monica Crugnola; Florian Heidel; Costanza Bosi; Daniela Bartoletti; Giuseppe Auteri; Lucia Catani; Antonio Cuneo; Franco Aversa; Gianpietro Semenzato; Michele Cavo; Nicola Vianelli; Giulia Benevolo
Journal:  Leuk Res       Date:  2018-10-05       Impact factor: 3.156

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.

Authors:  Haifa Kathrin Al-Ali; Martin Griesshammer; Lynda Foltz; Giuseppe A Palumbo; Bruno Martino; Francesca Palandri; Anna Marina Liberati; Philipp le Coutre; Carmen García-Hernández; Andrey Zaritskey; Renato Tavares; Vikas Gupta; Pia Raanani; Pilar Giraldo; Mathias Hänel; Daniela Damiani; Tomasz Sacha; Catherine Bouard; Carole Paley; Ranjan Tiwari; Francesco Mannelli; Alessandro M Vannucchi
Journal:  Br J Haematol       Date:  2020-02-04       Impact factor: 6.998

6.  Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.

Authors:  Francesca Palandri; Massimo Breccia; Massimiliano Bonifacio; Nicola Polverelli; Elena M Elli; Giulia Benevolo; Mario Tiribelli; Elisabetta Abruzzese; Alessandra Iurlo; Florian H Heidel; Micaela Bergamaschi; Alessia Tieghi; Monica Crugnola; Francesco Cavazzini; Gianni Binotto; Alessandro Isidori; Nicola Sgherza; Costanza Bosi; Bruno Martino; Roberto Latagliata; Giuseppe Auteri; Luigi Scaffidi; Davide Griguolo; Malgorzata Trawinska; Daniele Cattaneo; Lucia Catani; Mauro Krampera; Roberto M Lemoli; Antonio Cuneo; Gianpietro Semenzato; Robin Foà; Francesco Di Raimondo; Daniela Bartoletti; Michele Cavo; Giuseppe A Palumbo; Nicola Vianelli
Journal:  Cancer       Date:  2019-12-20       Impact factor: 6.860

7.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

Review 8.  The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.

Authors:  Mario Tiribelli; Francesca Palandri; Emanuela Sant'Antonio; Massimo Breccia; Massimiliano Bonifacio
Journal:  Bone Marrow Transplant       Date:  2019-09-18       Impact factor: 5.483

9.  Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Authors:  Francesca Palandri; Giuseppe Alberto Palumbo; Massimiliano Bonifacio; Mario Tiribelli; Giulia Benevolo; Bruno Martino; Elisabetta Abruzzese; Mariella D'Adda; Nicola Polverelli; Micaela Bergamaschi; Alessia Tieghi; Francesco Cavazzini; Adalberto Ibatici; Monica Crugnola; Costanza Bosi; Roberto Latagliata; Ambra Di Veroli; Luigi Scaffidi; Federico de Marchi; Elisa Cerqui; Barbara Anaclerico; Giovanna De Matteis; Marco Spinsanti; Elena Sabattini; Lucia Catani; Franco Aversa; Francesco Di Raimondo; Umberto Vitolo; Roberto Massimo Lemoli; Renato Fanin; Francesco Merli; Domenico Russo; Antonio Cuneo; Maria Letizia Bacchi Reggiani; Michele Cavo; Nicola Vianelli; Massimo Breccia
Journal:  Oncotarget       Date:  2017-06-27

10.  Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.

Authors:  Yan Beauverd; Kaveh Samii
Journal:  Int J Hematol       Date:  2014-07-18       Impact factor: 2.490

View more
  9 in total

Review 1.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

Review 2.  Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.

Authors:  Giuseppe G Loscocco; Alessandro M Vannucchi
Journal:  Int J Hematol       Date:  2022-03-29       Impact factor: 2.490

3.  Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.

Authors:  Joseph Pidala; Kelly Walton; Hany Elmariah; Jongphil Kim; Asmita Mishra; Nelli Bejanyan; Taiga Nishihori; Farhad Khimani; Lia Perez; Rawan G Faramand; Marco L Davila; Michael L Nieder; Elizabeth M Sagatys; Shernan G Holtan; Nicholas J Lawrence; Harshani R Lawrence; Bruce R Blazar; Claudio Anasetti; Said M Sebti; Brian C Betts
Journal:  Clin Cancer Res       Date:  2021-03-22       Impact factor: 13.801

4.  The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.

Authors:  Theodoros Karantanos; Patric Teodorescu; Brandy Perkins; Ilias Christodoulou; Christopher Esteb; Ravi Varadhan; Eric Helmenstine; Trivikram Rajkhowa; Bogdan C Paun; Challice Bonifant; W Brian Dalton; Lukasz P Gondek; Alison R Moliterno; Mark J Levis; Gabriel Ghiaur; Richard J Jones
Journal:  Sci Adv       Date:  2022-02-18       Impact factor: 14.136

Review 5.  The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.

Authors:  John O Mascarenhas; Srdan Verstovsek
Journal:  Cancer       Date:  2022-04-06       Impact factor: 6.921

Review 6.  JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.

Authors:  Charlotte Ej Downes; Barbara J McClure; Daniel P McDougal; Susan L Heatley; John B Bruning; Daniel Thomas; David T Yeung; Deborah L White
Journal:  Front Cell Dev Biol       Date:  2022-07-12

7.  Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.

Authors:  Aaron T Gerds; Jingbo Yu; Robyn M Scherber; Dilan Paranagama; Jonathan K Kish; Jay Visaria; Mukul Singhal; Srdan Verstovsek; Naveen Pemmaraju
Journal:  Acta Haematol       Date:  2022-01-10       Impact factor: 3.068

Review 8.  Momelotinib: an emerging treatment for myelofibrosis patients with anemia.

Authors:  Helen T Chifotides; Prithviraj Bose; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2022-01-19       Impact factor: 17.388

9.  Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients.

Authors:  Annabelle J Anandappa; Gabriela S Hobbs; Bimalangshu R Dey; Areej El-Jawahri; Matthew J Frigault; Steven L McAfee; Paul V O'Donnell; Thomas R Spitzer; Yi-Bin Chen; Zachariah DeFilipp
Journal:  Oncologist       Date:  2021-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.